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ABSTRACT
Introduction: Cutaneous melanoma (CM) is an
aggressive skin cancer entity, causing most skin
cancer-related deaths. Autoimmune disorders
have been described as potential paraneoplastic
complications. The purpose of this study was to
elucidate the possibility of a combinatory
paraneoplastic affection of the retina and
cochlea in patients with CM.
Methods: Sera samples from CM patients were
used for indirect immunofluorescence on
histological retinal and cochlear sections.
Furthermore, the serum specimen of a patient
with symptomatic affection of both organs was
analyzed by multiplex ELISA (enzyme-linked
immunosorbent assay) for various cytokines
including CD163 (cluster of differentiation
163).
Results: Eleven patients were diagnosed with
CM. Autoantibodies against structures of the
inner ear were confirmed in all patients who
were tested positive for antiretinal antibodies as
well. CD163 was significantly elevated in the
double-symptomatic patient, who developed
metastatic disease.
Conclusion: Paraneoplastic disease of CM can
affect more than one organ and this affect may
be correlated with the individual prognosis.
Therefore, a thorough anamnesis is needed to
avoid missing potential symptoms.
Keywords: Cutaneous melanoma; Inner ear;
Paraneoplastic syndrome; Retina
INTRODUCTION
Cutaneous melanoma (CM) is a potentially
aggressive form of skin cancer and its
incidence continues to rise with over 250,000
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new cases annually worldwide [1]. CM accounts
for the majority of skin cancer-related deaths
[1]. A large variance in survival rates, depending
on the extent of disease, exists [2]. Fortunately,
the previously dismal prognosis of this disease is
improving with recent advances in systemic
therapy.
CM derives from neuroectodermal
melanocytes. These melanocytes cannot only
be found in the skin and hair follicles, but also
in the eye and the inner ear. CM is an
immunogenic tumor type, which is frequently
associated with spontaneous autoimmune
manifestations [3]. In this perspective, the
symptoms might be interpreted as an attempt
by the immune system to develop antitumor
response.
Autoimmune retinopathy has been
described as a paraneoplastic manifestation of
CM [4, 5]. Reactive development of antiretinal
antibodies with resulting visual impairment is
still a poorly understood pathology. Patients
describe early symptoms as the presence of
sparkles and shimmers (photopsia) as well as
blind spots in their vision. On clinical
examination, early stages of retinopathy may
be difficult to see morphologically, but an
electroretinogram (ERG), which measures a
standardized evoked response of
photoreceptors and subsequent neurons in the
retina, is able to demonstrate retinal
dysfunction and helps to find the right
diagnosis [6].
It has been hypothesized that the inner ear
could be a target for a CM-mediated
autoimmune response, in which the immune
system produces antibodies that cross-react
with cells of the organ of Corti, leading to
disorders such as vertigo, hearing loss, nausea,
and tinnitus [7].
Herein, we aim to demonstrate the
histoserological evidence of antibodies against
retinal as well as inner ear cells in CM patients.
We would like to introduce this condition as
MARCo (melanoma-associated retinopathy and
cochleopathy).
METHODS
Patient data as well as blood samples of CM
patients in Lu¨beck (CMPL) and Homburg
(CMPH) were evaluated for this study after
informed consent. A healthy individual’s
blood sample was used as non-melanoma
control (NMC). The blood was allowed to clot
by leaving it undisturbed at room temperature
(RT). The clot was removed and following
centrifugation the resulting supernatant was
collected as designated serum. Aliquots were
stored at -80 C. To verify the specific binding
of antibodies in the sera, we used a
commercially available unspecific human IgG
(Perbio Science, Bonn, Germany) as antibody
control (AC).
Frozen macaque (Macaca fascicularis) retina
sections (8 lm) were thawed at RT and
rehydrated in phosphate buffered saline (PBS).
Demineralized paraffin cochlea sections (10 lm)
from the same animals were deparaffinized and
rehydrated in PBS as well. After applying
blocking buffer, the slides were incubated with
the different probes (AC, NMC, CMPL,
CMPH1-10) for 2 h at RT. The slides were then
repeatedly washed and incubated with a
biotin-conjugated-goat-anti-human secondary
antibody (Rockland, Gilbertsville, PA, USA) for
1 h at RT. After another washing procedure,
slides were incubated with Alexa488-conjugated
streptavidin (kex/kem = 495 nm/519 nm; Life
Technologies, Darmstadt, Germany) for 1 h
and 4’,6-diamidino-2-phenylindole (DAPI kex/
kem = 358 nm/461 nm, 1 lg/ml Life
Technologies, Darmstadt, Germany) for
10 min at RT. Finally, the slides were mounted
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using Mowiol mounting medium (Sigma
Aldrich, Steinheim, Germany), and images
were taken with an inverse fluorescence
microscope (Leica DMI6000 B, Leica
Microsystems, Wetzlar, Germany) using the
same parameters (magnification, exposure
Fig. 1 Characteristic electrophysiological ﬁndings in
melanoma-associated retinopathy (MAR). a Scotopic
(rod responses) full-ﬁeld electroretinogram (ERG):
Negative ERG with missing b-waves on the right eye
and normal responses on the left one. b Photopic
(cone responses) full-ﬁeld ERG: Negative ERG with
missing b-waves on both eyes, however, this was more
pronounced on the right eye
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time, contrast and saturation) for all specimens.
Depending on the tissue (retina vs. cochlea), the
same filter and threshold parameters were
applied to all images before assessment by
semi-quantitative measurement of the number
of Alexa488-positive particles, using ImageJ
software (Version 1.48b, NIH, Bethesda, USA)
in a blinded fashion.
In addition, the NMC and MPL samples were
examined for various cytokines (IFN-c, IL1-13,
IL17, IL23, CD14, CD163, TNFa) using a fully
quantitative multiplex ELISA, according to
manufacturer’s instruction (Q-PlexTM Human
Cytokine Array, Quansys Biosciences, Logan,
UT, USA). Data were captured on the Odyssey
infrared imaging system (Li-Cor Biosciences,
Lincoln, NE, USA) and analyzed using Quansys
Q-view PlusTM software (Quansys Biosciences,
Logan, UT, USA).
All experiments were conducted thrice.
Fold-changes relative to NMC are expressed as
the mean ± standard deviation. Statistical
analysis was performed with Prism (Version 6,
GraphPad, La Jolla, USA) using an unpaired
Student t test with p\0.05 considered
significant. This article does not contain any
new studies with human or animal subjects
performed by any of the authors.
RESULTS
All 11 patients were diagnosed with cutaneous
melanoma. Seven of them (CMPL, CMPH2,
CMPH4, CMPH6-8, CMPH10) had a positive
serology (reference laboratory in Homburg,
Germany) for melanoma-associated
retinopathy (MAR), even though not all of
them were symptomatic. When symptomatic,
patients were presented with recurrent
scintillating scotoma, color vision deficiency,
night blindness or visual field constriction.
In most cases, symptoms correlated with
electrophysiological findings like for CMPL. In
this specific case, the patient was previously
diagnosed with two episodes of CM. While
fundoscopic examination did not show any
pathological changes, the ERG demonstrated a
significant b-wave reduction, particularly of the
right eye (Fig. 1).
Indirect immunofluorescence on the retinal
specimen did show specific staining of the
neuronal layers consisting of photoreceptors,
bipolar cells, and ganglion cells (Fig. 2a).
As CMPL did describe onset of tinnitus since
recurrence of CM, we also performed indirect
immunofluorescence on the cochlear specimen.
Here, specific stainings of the inner and outer hair
cells as well as Reissner’s membrane were evident
(Fig. 2b). This result was also found to different
extents in seven other CM patients. Interestingly,
these were the same patients, who had previously
been tested positive for MAR (Fig. 3).
Fig. 2 Indirect immunoﬂuorescence ﬁndings of the retina
and cochlea. a Stainings of the retina specimen showed no
signal for the isotype antibody control (AC) and almost
none for the non-melanoma control (NMC). However,
several of our cutaneous melanoma (CM) patients, such as
cutaneous-melanoma patient Lu¨beck (CMPL), showed
speciﬁc immunoﬂuorescence (Alexa488) around the
photoreceptor cell nuclei (ONL) as well as inner/outer
segments (IS/OS), the bipolar cells (inner nuclear layer
INL) and ganglion cells (ganglion cell layer GCL). In all
three panels the retinal pigment cells (RPE) showed
typical autoﬂuorescence. Cell nuclei were stained with
4’,6-diamidino-2-phenylindole (DAPI, blue). Scale bar is
100 lm. b Stainings of the cochlea-specimen showed no
signal for the isotype AC and almost none for the
non-melanoma control (NMC). However, several of our
CM patients, such as CMPL, showed speciﬁc
immunoﬂuorescence (Alexa488) in the organ of Corti,
which consists of inner and outer hair cells (IHC and
OHC). Furthermore, positive immunoﬂuorescence was
captured around Reissner’s membrane (RM) and the
tectorial membrane (TM). Cell nuclei were stained with
DAPI (blue). Scale bar is 100
c
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Multiplex ELISA showed a significant
elevated serum level of CD163 in CMPL
compared to NMC (Fig. 4). All other cytokines
were not significantly different.
DISCUSSION
MAR was first described in 1988 [8]. Most cases
have been associated with CM. However, uveal
melanoma has also been implicated [5]. Clinical
features of MAR typically reflect
photoreceptor-mediated dysfunction.
Diagnostic confidence is increased by serology,
visual function tests, and electrophysiology.
The ERG pattern in MAR is classically
electronegative. A preserved dark-adapted
a-wave, indicating normal photoreceptor
function, is followed by a markedly attenuated
b-wave, reflecting either bipolar cell
dysfunction or disruption of synaptic
transmission between photoreceptors and
bipolar cells [9].
Anti-bipolar cell antibodies have been
considered the characteristic marker of MAR.
It has been suggested that these autoantibodies,
directed against the postsynaptic receptors of
the bipolar cells, interrupt signal transmission
with associated photoreceptors [10].
Our results, correlated almost perfectly,
except for CMPH9, with those of the external
reference laboratory, which suggests a sufficient
validity of our method. Negative results of the
controls (AC and NMC) underline this fact.
Tinnitus is an abnormal noise perceived in
one or both ears, or in the head and is usually
associated with damage to the auditory system
of the inner ear [11]. Inner ear pathology in the
setting of a systemic autoimmune disorder
might be immune-mediated. However, isolated
immune-mediated inner ear disorders also
Fig. 3 Results of semi-quantitative evaluation. Values were
normalized to NMC. All patients, who were tested positive
for antibodies against the retina (MAR AB internal), also
showed positive staining on the cochlea slides, in different
degrees. Only two patients received IFN-a therapy
(CMPH6 and CMPH8). *Signiﬁes p\0.05 (unpaired
Student t test). Antibody control (AC), non-melanoma
control (NMC), cutaneous-melanoma patient Lu¨beck
(CMPL), cutaneous-melanoma patient Homburg
(CMPH), melanoma-associated retinopathy antibody
proof (MAR AB), interferon-a (IFN-a)
Fig. 4 Cutaneous-melanoma patient Lu¨beck (CMPL)
serum levels of CD163 (Cluster of Differentiation 163).
Results were normalized to the non-melanoma control
(NMC). This speciﬁc cutaneous melanoma patient, who
was affected by rapid metastatic disease, showed signiﬁcant
elevated levels of CD163. *Signiﬁes p\0.05 (unpaired
Student t test)
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occur. The pathogenesis of immune-mediated
inner ear disorders remains largely unknown,
although various mechanisms have been
suggested such as humoral antibody
production, autoreactive T cells, immune
complex deposition, and vasculitis [12].
Paraneoplastic audiovestibular disorders
associated with CM have already been
hypothesized, but not yet confirmed [7].
Despite having confirmed the presence of
melanoma-associated autoantibodies against
retinal tissue, we have to consider other
sources of autoimmunity. Type I interferons,
which are mostly a-interferons (IFN-a), are used
to treat CM, as it was done in a few of our
patients (CMPL, CMPH6, and CMPH8) [13].
Side effects are not uncommon and include
exacerbation of pre-existing autoimmune
disorders or the de novo induction of
autoimmunity. These adverse effects are
attributed to the immunomodulatory
properties of IFN-a, and should be
distinguished from autoimmunity associated
with melanoma. However, five patients
diagnosed with MARCo were not treated with
IFN-a, which suggests that in this context IFN-a
treatment is a weaker confounding factor.
Finally, we aimed at looking whether the
presence of multiple autoimmune disorders in
melanoma patients might be of prognostic
value, because this would allow oncologists to
provide appropriate therapy by escalation of the
treatment regimen. Various cytokines, such as
CD163, have been discussed as potential
prognostic indicators [14]. The hemoglobin
receptor CD163 is a specific
monocyte-macrophage protein, predominantly
expressed on anti-inflammatory cell types. It is a
promising marker to monitor macrophage
activation as macrophages are key cells in the
pathogenesis of several infectious,
autoimmune, and malignant diseases [15].
Elevated CD163 serum levels have been shown
to be a predictor of poor survival in CM, which
was also the case in CMPL, who rapidly
developed metastatic disease with a fatal
outcome [16]. However, further research is
needed to confirm the value of
melanoma-associated autoimmunity and
inflammatory cytokines as a prognostic tool.
CONCLUSION
To the best of our knowledge this is the first
report with histoserological confirmation of
melanoma-associated retinopathy and
cochleopathy, henceforth known as MARCo.
This autoimmune paraneoplastic entity should
be addressed during anamnesis as it might be of
prognostic significance.
ACKNOWLEDGMENTS
No funding or sponsorship was received for this
study or publication of this article. All named
authors meet the International Committee of
Medical Journal Editors (ICMJE) criteria for
authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval to the
version to be published. The authors would like
to thank Christine O¨ru¨n for excellent technical
assistance.
Disclosures. Mahdy Ranjbar, Armin Mohi,
Claudia Pfo¨hler, Salvatore Grisanti, and Martin
Rudolf have nothing to disclose.
Compliance with Ethics Guidelines. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors. Informed consent was obtained
from the patients for using patient data and
blood samples.
Dermatol Ther (Heidelb) (2016) 6:659–666 665
Open Access. This article is distributed under
the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit to
the original author(s) and the source, provide a
link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Singh BP, Salama AKS. Updates in therapy for
advanced melanoma. Cancers. 2016;8(1):17.
doi:10.3390/cancers8010017.
2. Malczewski A, Marshall A, Payne MJ, Mao L,
Bafaloukos D, Si L, et al. Intravenous high-dose
interferon with or without maintenance treatment
in melanoma at high risk of recurrence:
meta-analysis of three trials. Cancer Med.
2016;5:17–23.
3. Bouwhuis MG, Ten Hagen TLM, Suciu S, Eggermont
AM. Autoimmunity and treatment outcome in
melanoma. Curr Opin Oncol. 2011;23:170–6.
4. Pfo¨hler C, Haus A, Palmowski A, Ugurel S, Ruprecht
KW, Thirkill CE, et al. Melanoma-associated
retinopathy: high frequency of subclinical
findings in patients with melanoma. Br J
Dermatol. 2003;149:74–8.
5. Lu Y, Jia L, He S, Hurley MC, Leys MJ, Jayasundera
T, et al. Melanoma-associated retinopathy: a
paraneoplastic autoimmune complication. Arch
Ophthalmol Chic Ill. 2009;1960(127):1572–80.
6. Grange L, Dalal M, Nussenblatt RB, Sen HN.
Autoimmune retinopathy. Am J Ophthalmol.
2014;157(266–272):e1.
7. Barozzi S, Ginocchio D, Socci M, Alpini D, Cesarani
A. Audiovestibular disorders as autoimmune
reaction in patients with melanoma. Med
Hypotheses. 2015;85:336–8.
8. Berson EL, Lessell S. Paraneoplastic night blindness
with malignant melanoma. Am J Ophthalmol.
1988;15(106):307–11.
9. Keltner JL, Thirkill CE, Yip PT. Clinical and
immunologic characteristics of
melanoma-associated retinopathy syndrome:
eleven new cases and a review of 51 previously
published cases. J Neuro-Ophthalmol Off J N Am
Neuro-Ophthalmol Soc. 2001;21:173–87.
10. Alexander KR, Fishman GA, Peachey NS, Marchese
AL, Tso MO. On response defect in paraneoplastic
night blindness with cutaneous malignant
melanoma. Investig Ophthalmol Vis Sci.
1992;33:477–83.
11. Sindhusake D, Golding M, Wigney D, Newall P,
Jakobsen K, Mitchell P. Factors predicting severity
of tinnitus: a population-based assessment. J Am
Acad Audiol. 2004;15:269–80.
12. Lunardi C, Bason C, Leandri M, Navone R, Lestani
M, Millo E, et al. Autoantibodies to inner ear and
endothelial antigens in Cogan’s syndrome. Lancet.
2002;21(360):915–21.
13. Sabel MS, Sondak VK. Pros and cons of adjuvant
interferon in the treatment of melanoma.
Oncologist. 2003;8:451–8.
14. Neagu M, Constantin C, Dumitrascu GR, Lupu AR,
Caruntu C, Boda D, et al. Inflammation markers in
cutaneous melanoma-edgy biomarkers for
prognosis. Discoveries. 2015;31(3):e38.
15. Graversen JH, Svendsen P, Dagnæs-Hansen F, Dal J,
Anton G, Etzerodt A, et al. Targeting the
hemoglobin scavenger receptor cd163 in
macrophages highly increases the
anti-inflammatory potency of dexamethasone.
Mol Ther. 2012;20:1550–8.
16. Jensen TO, Schmidt H, Møller HJ, Høyer M,
Maniecki MB, Sjoegren P, et al. Macrophage
Markers in serum and tumor have prognostic
impact in American Joint Committee on cancer
stage I/II melanoma. J Clin Oncol.
2009;10(27):3330–7.
666 Dermatol Ther (Heidelb) (2016) 6:659–666
